GENinCode, EVERSANA Enter Major U.S. Commercialization Pact

GENinCode UK Ltd., a company focused on predictive genetics for the prevention of cardiovascular disease, has selected EVERSANA Life Sciences LLC as its launch and commercialization partner to access the U.S. market for GENinCode’s portfolio of polygenic cardiovascular disease (CVD) products focused on genetic risk.

EVERSANA is a provider of global commercial services to the life sciences industry. In the U.S., GENinCode will use EVERSANA’s COMPLETE Commercialization model of services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, health economics and outcomes research and compliance, each optimized by data and predictive analytics. The partnership will accelerate the launch of GENinCode’s first product Cardio inCode for the risk assessment of CVD in primary prevention.

GENinCode specialises in polygenic risk assessment for the onset of cardiovascular disease with the Company’s technology providing clinicians with genetic risk assessment and AI bioinformatics to inform, predict and prevent cardiovascular events.

CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischaemia, and some chronic kidney disease) and venous thromboembolism.